LGALS9 and neoplasm: To overcome the immunosuppressive tumour microenvironment of PDAC, an EV-based dual DDS of siR-galectin-9 was developed to block the galectin-9/dectin-1 axis and reverse immunosuppression caused by tumour-associated macrophages, and prodrug oxaliplatin (OXA), to act as immunogenic cell death trigger and kill the tumour cells by inhibiting DNA synthesis and repair.